Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DS-8895a in Advanced Solid Tumors
jRCT2080222257Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-8895a in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of DS-8895a and Pharmacokinetics of DS-8895a.
02
Drugs
DS-8895a
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222257.